|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | hazomib, an investigational oral proteasome inhibitor ( PI ), in combination with lenalidomide and dexamethasone ( IRd ), significantly extends progression-free survival ( PFS ) for patients ( Pts ) with relapsed and/or refractory multiple myeloma ( RRMM ) : the phase 3 tourmaline-MM1 study ( NCT01564537 ) 显示文摘 | Moreau P Masszi T Grzasko N | 2015 | Blood2015，126，23： | 1 |
| 2 | Case- adjusted bortezomib-based strategy in routine therapy of relapsed / refractory multiple myeloma shown to be highly effective-a report by Polish Myeloma Study Group 显示文摘 | Waher-Croneck A Grzasko N Soroka-Wojtaszko M | 2014 | Leuk Res2014，38，7： | 1 |
| 3 | Optimizing the Treatment of Patients With Multiple Myeloma and Renal Impairment显示文摘 | Grzasko N Morawska M Hus M | 2015 | Clin Lymphoma Myeloma Leuk2015，15，4： | 1 |
| 4 | Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients显示文摘 | Norbert Grzasko Marek Hus Andrzej Pluta Artur Jurczyszyn Adam Walter‐Croneck Marta Morawska Sylwia Chocholska Roman Hajek Anna Dmoszynska | 2012 | Hematol Oncol2012，，1： | 1 |
| 5 | Stimulation of erythropoiesis by thalidomide in multiple myeloma patients:its influence on FasL,TRAIL and their receptors on erythroblasts显示文摘 | Grzasko N Dmoszynska A Hus M | 2006 | Haematol2006，91，3： | 1 |
| 6 | Stimulation of erythropoiesis by thalidomide in multiple myelorna patients: its influence on FasL, TRAIL and their receptors on erythroblasts显示文摘 | Grzasko N Dmoszynska A Hus M | 2006 | Haematologica2006，91，3： | 1 |
| 7 | Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma显示文摘 | MOREAU P MASSZI T GRZASKO N et ol | 2016 | N Engl J Med2016，374，17： | 1 |
| 8 | Stimulation of erythropoiesis by thalidomide in multiple myeloma patients:its influence on FasL,TRAIL and their receptors on erythroblasts显示文摘 | Grzasko N Dmoszynska A Hus M | 2006 | Haematologica2006，91，3： | 1 |
| 9 | Ixazomib, an investigational combination with lenalidomide and dexamethasone (IRd), significantly extents progression free survival (PFS) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 Tourmaline-MM study (NCT 01564537) 显示文摘 | Moreau P Masszi T Grzasko N oral proteasome inhibitor (PI) in | 2015 | Blood (ASH annual meeting Abstracts)2015，126，23： | 1 |
| 10 | Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice显示文摘 | Jurczyszyn A Grzasko N Gozzetti A | | Am J Hematol0，91，6： | 1 |
| 11 | Therapyrelated peripheral neuropathy in multiple myeloma patients显示文摘 | MORAWSKA M GRZASKO N KOSTYRA M | 2015 | Hematol Oncol2015，33，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员